The effect of using different contrast agents in CT scan on radiation dose during radiotherapy
Phase 4
- Conditions
- Malignant neoplasm of prostateProstate Cancer.
- Registration Number
- IRCT20190814044528N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
Prostate cancer patients who are referred to the CT scan ward for CT imaging and don't have the exclusion criteria
Exclusion Criteria
Patients under 18 years old
Patients with kidney problems
Diabetic patients
Patients with a history of asthma and immunological allergies
People who had allergy to the use of contrast agents in the past
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Radiation dose of the patient. Timepoint: After CT imaging with injection of contrast material. Method of measurement: Radiotherapy treatment planning software (TPS).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence contrast agent impact on radiation dose calculation in prostate cancer CT scans?
How do Omnipaque, Visipaque, and Ultravist compare in modifying radiation therapy planning for prostate malignancies?
Are there specific biomarkers that correlate with contrast agent efficacy in prostate cancer radiotherapy imaging?
What adverse events are associated with contrast agent use during CT scans for prostate cancer radiotherapy planning?
How do different contrast agents affect dose distribution accuracy in prostate cancer TPS simulations?